Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma
Open Access
- 21 June 2013
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 32 (3), 557-567
- https://doi.org/10.3892/ijmm.2013.1424
Abstract
Circulating microRNA expression levels can serve as diagnostic/prognostic biomarkers in several types of malignant tumors; however, to our knowledge, there have been reports describing their value in cervical squamous cell carcinoma (SCC). In this study, we used hybridization arrays to compare the microRNA expression profiles in cervical squamous cell carcinomas (SCC) samples among patients with lymph node metastasis (LNM) or without LNM; 89 microRNAs were found to fit our inclusion criteria. Using quantitative PCR (qPCR), we examined the expression levels of these microRNAs in cervical cancer tissue, as well as in serum from patients and healthy women. We compared the expression levels between patients with LNM (n=40) and those without LNM (n=40) and healthy controls (n=20). Using regression analysis, we generated a comprehensive set of marker microRNAs and drew the fitted binormal receiver operating characteristic (ROC) curves to access the predictive value. We identified 6 serum microRNAs that can predict LNM in cervical SCC patients; these microRNAs were miR-1246, miR-20a, miR-2392, miR-3147, miR-3162-5p and miR-4484. The area under the curve (AUC) of the comprehensive set of serum microRNAs predicting LNM was 0.932 (sensitivity, 0.856; specificity, 0.850). The predictive value of the serum microRNAs was inferior to that in tissue (AUC 0.992; sensitivity, 0.967; specificity, 0.950; P=0.018). We compared the LNM predictive value of serum microRNAs and SCC antigen (SCC-Ag) by drawing fitted binormal ROC curves However, serum microRNA analysis is by far superior to serum SCC‑Ag analysis (AUC 0.713; sensitivity, 0.612; specificity, 0.700; P<0.0001). Serum microRNAs are a good predictor of LNM with clinical value in early-stage cervical SCC.Keywords
This publication has 56 references indexed in Scilit:
- MiRNA-199a-3p in Plasma as a Potential Diagnostic Biomarker for Gastric CancerAnnals of Surgical Oncology, 2012
- Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancerInternational Journal of Clinical Oncology, 2007
- Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC)Cancer Letters, 2007
- Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92Oncogene, 2007
- The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapyInternational Journal of Gynecologic Cancer, 2006
- MicroRNA Gene Expression Deregulation in Human Breast CancerCancer Research, 2005
- Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trialsEuropean Journal Of Cancer, 2003
- Application of Tumor Markers CEA, TPA, and SCC-Ag in Patients with Low-Risk FIGO Stage IB and IIA Squamous Cell Carcinoma of the Uterine CervixGynecologic Oncology, 2000
- Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.1997
- Immunohistochemical evaluation of squamous cell carcinoma antigen and s-100 protein-positive cells in human malignant esophageal tissuesCancer, 1990